Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXS-05 in Major Depressive Disorder (GEMINI)
NCT04019704Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dextromethorphan + bupropion in major depressive disorder (MDD), sponsored by Axsome Therapeutics, Inc.. Started Jun 2019; status: completed.
02
Drugs
dextromethorphan + bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04019704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019704.